Welcome to the e-CCO Library Archive!

search
                             
search by: 
Filter:
P412. Pharmacokinetics of adalimumab in adult patients with moderately to severely active ulcerative colitis
Authors:

W. Awni1, D. Eckert2, S. Sharma1, N. Mostafa1, P. Noertersheuser2, R. Pradhan1, A. Robinson1, W. Sandborn3, S. Hanauer4, J.-F. Colombel5, R. Thakkar1, 1Abbott Laboratories, United States, 2Abbott Laboratories, Germany, 3University of California, San Diego, United States, 4University of Chicago, United States, 5Centre Hospitalier Universitaire de Lille, Hôpital Claude Huriez, Lille, France

P412

Fecal calprotectin as predictor of relapse in asymptomatic Ulcerative Colitis

Authors:

E. Leo Carnerero*, G. Ontanilla Clavijo, C. Trigo Salado, V. Aguilera Jaldo, M.D. De La Cruz Ramirez, A. Araujo Miguez, J.M. Herrera Justiniano, J.L. Marquez Galan

HU Virgen del Rocío, UGC Digestive Diseases, Seville, Spain

P413.

Management of ulcerative colitis patients in clinical practice: results of a nationwide survey (CROSSOVER) conducted in Spain

Authors:

M. Barreiro-de Acosta1, I. Ordás2, R. Camargo3, C. Taxonera4, 1University Hospital Santiago de Compostela, Gastroenterology, Santiago, Spain, 2Hospital Clínic Barcelona, Gastroenterology, Barcelona, Spain, 3Hospital Clinico Virgen de la Victoria, Gastroenterology, Malaga, Spain, 4Hospital Clinico San Carlos, Department Gastroenterology, Madrid, Spain

P413. How do psychological variables influence health-related quality of life in Crohn's disease patients?
P413. Persistence with 5-ASA therapy in the UK: a matched sample study
Authors:

A. Robinson1, M. Hankins2, G. Wiseman3, M. Jones4, 1Salford Royal NHS Foundation Trust, Salford, United Kingdom, 2University of Southampton, Southampton, United Kingdom, 3Medical Affairs, Warner Chilcott UK Ltd, Weybridge, United Kingdom, 4Health Informatics Research, Sciensus Ltd, Brighton, United Kingdom

P413

Healthcare expenditures for inflammatory bowel disease peak in patients with a short disease duration

Authors:

M. Severs*1, M.E. van der Valk1, M.-J. Mangen2, M. van der Have1, G. Dijkstra3, A.A. van Bodegraven4, 5, H.H. Fidder1, D.J. de Jong6, M. Pierik7, J. van der Woude8, M.J.L. Romberg- Camps4, C.H.M. Clemens9, J.M. Jansen10, P.C. van de Meeberg11, N. Mahmmod12, A.E. van der Meulen- de Jong13, C.Y. Ponsioen14, C.J. Bolwerk15, J.R. Vermeijden16, P.D. Siersema1, M. Leenders1, B. Oldenburg1

1University Medical Centre Utrecht, Gastroenterology and Hepatology, Utrecht, Netherlands, 2University Medical Centre Utrecht, Julius center for health sciences and primary care, Utrecht, Netherlands, 3University Medical Centre Groningen, Gastroenterology and Hepatology, Groningen, Netherlands, 4ORBIS medical center, Gastroenterology and Hepatology, Sittard, Netherlands, 5VU medical center, Gastroenterology and Hepatology, Amsterdam, Netherlands, 6University Medical Center st. Radboud, Gastroenterology and Hepatology, Nijmegen, Netherlands, 7University Medical Center Maastricht, Gastroenterology and Hepatology, Maastricht, Netherlands, 8Erasmus Medical Center, Gastroenterology and Hepatology, Rotterdam, Netherlands, 9Diaconessenhuis, Gastroenterology and Hepatology, Leiden, Netherlands, 10Onze Lieve Vrouwe Gasthuis, Gastroenterology and Hepatology, Amsterdam, Netherlands, 11Slingeland Hospital, Gastroenterology and Hepatology, Doetinchem, Netherlands, 12Antonius Hospital, Gastroenterology and Hepatology, Nieuwegein, Netherlands, 13Leiden University Medical Centre, Gastroenterology and Hepatology, Leiden, Netherlands, 14Academic Medical Centre Amsterdam, Gastroenterology and Hepatology, Amsterdam, Netherlands, 15Reinier de Graaf Groep, Gastroenterology and Hepatology, Delft, Netherlands, 16Meander Medical Centre, Gastroenterology and Hepatology, Amersfoort, Netherlands

P414.

Management of gastrointestinal Behçet's disease refractory to conventional treatment

Authors:

I. Hatemi1, G. Hatemi2, Y. Erzin1, A.F. Celik1, 1Istanbul University Cerrahpasa Medical Faculty, Gastroenterology, Istanbul, Turkey, 2Istanbul University Cerrahpasa Medical Faculty, Rheumatology, Istanbul, Turkey

P414. Anemia in a population based IBD cohort – still high prevalence after one year
P414. Perianal mucinous adenocarcinoma arising from a fistulous tract in Crohn's disease
Authors:

E. Krauss1, A. Agaimy2, H. Albrecht3, W. Hohenberger4, M. Neurath1, K. Matzel4, J. Mudter1, 1University of Erlangen-Nuremberg, Department of Medicine 1, Erlangen, Germany, 2University of Erlangen-Nuremberg, Institute of Pathology, Erlangen, Germany, 3University of Erlangen-Nuremberg, Department of Medicine 1, D-91054 Erlangen, Germany, 4University of Erlangen-Nuremberg, Department of Abdominal Surgery, Erlangen, Germany

P414

Cannabidiol for symptomatic treatment of ulcerative colitis: Results from a randomised, double-blind, placebo-controlled, parallel group, multi-centred pilot study

Authors:

P. Irving*1, T. Iqbal2, C. Nwokolo3, S. Subramanian4, S. Bloom5, N. Prasad6, A. Hart7, C. Murray8, J. Lindsay9, A. Taylor10, R. Barron10, S. Wright11

1Guy's and St Thomas' NHS Foundation Trust, Department of Gastroenterology, London, United Kingdom, 2University Hospitals Birmingham NHS Foundation Trust, Department of Gastroenterology, Birmingham, United Kingdom, 3University Hospitals Coventry and Warwickshire NHS Trust, Department of Gastroenterology, Coventry, United Kingdom, 4The Royal Liverpool and Broadgreen University Hospitals NHS Trust, Department of Gastroenterology, Liverpool, United Kingdom, 5University College London Hospitals NHS Foundation Trust, Department of Colorectal Surgery, London, United Kingdom, 6Wrightington, Wigan and Leigh NHS Foundation Trust, Department of Gastroenterology, Wigan, United Kingdom, 7The North West London Hospitals NHS Trust, Inflammatory Bowel Disease Unit, Middlesex, United Kingdom, 8Royal Free London NHS Foundation Trust, Department of Gastroenterology, London, United Kingdom, 9Barts Health NHS Trust, Department of Gastroenterology, London, United Kingdom, 10GW Pharmaceuticals plc, Medical Writing Department, Salisbury, United Kingdom, 11GW Pharmaceuticals plc, Research and Development, Salisbury, United Kingdom

P415.

MRI assessment of body composition in paediatric Crohn's disease; intra-abdominal adipose tissue association with disease severity

Authors:

D. Thangarajah1, K.E. Chappell2, C. Gale3, J.R. Parkinson1, J. Epstein4, W. Hyer4, K. Soondrum4, G. Frost5, J.M. Fell4, 1Imperial College, Section of Academic Neonatal Medicine, London, United Kingdom, 2Chelsea and Westminster NHS foundation trust, Radiology, London, United Kingdom, 3Imperial College, Section of Academic Neonatal medicine, London, United Kingdom, 4Chelsea and Westminster NHS foundation trust., Paediatric Gastroenterology department, London, United Kingdom, 5Imperial College, Nutrition and Dietetic Research Group, Faculty of Medicine, London, United Kingdom

P415. Low risk of lymphoma in inflammatory bowel diseases in Western Hungary. Results from a population-based incident cohort
P415. Perianal complete remission after combined therapy with seton placement and anti-TNF therapy for Crohn's disease: results of a Brazilian multicenter observational study
Authors:

P.G. Kotze1, I.C. Albuquerque2, A.d.L. Moreira3, C.R. Coy4, W.B. Tonini1, G.S. Formiga2, R.F. Leal4, M.d.L.S. Ayrizono4, A.T.P. Carvalho5, M. Olandoski6, L.M.S. Kotze7, 1Catholic University of Parana, Colorectal Surgery Unit, Curitiba – PR, Brazil, 2Heliópolis Hospital, IBD clinics, São Paulo – SP, Brazil, 3UERJ, Colorectal Surgery Unit, Rio de Janeiro – RJ, Brazil, 4Unicamp, Colorectal Surgery Unit, Campinas – SP, Brazil, 5UERJ, Gastroenterology Unit, Rio de Janeiro – RJ, Brazil, 6Catholic University of Parana, Statistics, Curitiba – PR, Brazil, 7Catholic University of Parana, Gastroenterology unit, Curitiba – PR, Brazil

P415

Fecal calprotectin and serum C-reactive protein predict outcome of infliximab induction therapy in inflammatory bowel disease.

Authors:

P.M. Hellström*1, H. Diaz1, M. Lonnkvist1, R. Befrits2

1Uppsala University, Department of Medical Sciences, Uppsala, Sweden, 2Karolinska Institutet, Department of medicine, Stockholm, Sweden

P416.

MDR1 C3435 gene polymorphism and several clinical risk factors associated with glucocorticoid dependence and resistance in inflammatory bowel disease

Authors:

L. Liu, R. Zhou, B. Xia, Zhongnan Hospital of Wuhan University School of Medicine, Gastroenterology, Wuhan, China

P416. Patients' beliefs and attitudes to their treatment of inflammatory bowel disease: multicenter study
Authors:

K.O. Kim1, B.I. Jang1, E.S. Kim2, E.Y. Kim3, C.H. Yang4, 1Yeungnam University College of Medicine, Division of Gastroenterogy, Department of Internal Medicine, Daegu, South Korea, 2Kyemyung University College of Medicine, Division of Gastroenterology and Hepatology, Department of Internal Medicine, Daegu, South Korea, 3Catholic University of Daegu School of Medicine, Division of Gastroenterology and Hepatology, Department of Internal Medicine, Daegu, South Korea, 4Dongguk University College of Medicine, Division of Gastroenterology and Hepatology, Department of Internal Medicine, Kyungju, South Korea

P416. The risk of thromboembolic events in patients with inflammatory bowel disease: 10 years of experience at our clinic
P416

Is faecal calprotectin (FC) a reliable marker of isolated small bowel Crohn's disease (CD) activity?

Authors:

B. Warner*1, E. Johnston1, M. Ward2, P. Irving1

1Guy's and St Thomas' NHS Foundation Trust, Department of Gastroenterology, London, United Kingdom, 2The Alfred Hospital, Department of Gastroenterology, Melbourne, Australia

P417.

Managing pediatric acute severe ulcerative colitis according to the 2011 ECCO-ESPGHAN Guidelines: Efficacy of infliximab as a rescue therapy

Authors:

G. D'Arcangelo, G. Di Nardo, M. Capponi, F. Nuti, F. Vassallo, F. Civitelli, F. Viola, S. Cucchiara, M. Aloi, Sapienza University of Rome, Pediatrics, Rome, Italy

P417. Multicenter, double-blinded, randomized, placebo-controlled, parallel-group study: evaluation of efficacy of mesalazine suppository in patients with ulcerative colitis with rectal inflammation
Authors:

K. Matsuoka1, M. Watanabe2, T. Hibi1, 1Keio University School of Medicine, Gastroenterology and Hepatology, Tokyo, Japan, 2Tokyo Medical and Dental University, Gastroenterology and Hepatology, Tokyo, Japan